secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125374
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed
--------------------------------------------------------------------------------

- Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.
- Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.
- Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.
- Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.
- Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/0000950170-24-125374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/xene-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer